Related Experiment Videos
Growth hormone secretion in chronic schizophrenia
Neuropsychobiology
|January 1, 1975
Summary
Growth hormone (GH) secretion in schizophrenic patients is highly variable and unaffected by haloperidol treatment. This study investigated GH response to insulin-induced hypoglycemia in schizophrenia patients undergoing haloperidol therapy.
Area of Science:
- Neuroendocrinology
- Psychopharmacology
- Clinical Psychiatry
Background:
- Schizophrenia is a complex psychiatric disorder with potential neuroendocrine dysregulation.
- Growth hormone (GH) secretion is influenced by various neurotransmitters and hormonal factors.
- Understanding GH regulation in schizophrenia is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the impact of haloperidol therapy on growth hormone (GH) secretion in schizophrenic patients.
- To assess the GH response to insulin-induced hypoglycemia before, during, and after haloperidol treatment.
- To explore the relationship between psychopathological features and GH secretion in schizophrenia.
Main Methods:
- 19 chronic schizophrenic patients (including hebephrenic and paranoid subtypes) received 6 mg of haloperidol intramuscularly daily for 30 days.
- Growth hormone (GH) response to insulin-induced hypoglycemia (0.1 IU/kg i.v.) was measured at baseline and on days 10, 20, and 30 of treatment.
- Psychopathological features were assessed daily using psychiatrist evaluations and the Wittenborn rating scale.
Main Results:
- Growth hormone (GH) secretion and response to insulin stimulation in schizophrenic patients exhibited significant variability.
- Haloperidol treatment did not demonstrate a significant effect on GH secretion or its response to insulin-induced hypoglycemia.
- No clear correlation was found between psychopathological changes and alterations in GH secretion during the study period.
Conclusions:
- Growth hormone (GH) secretion in schizophrenic patients is inherently variable and appears to be resistant to the modulatory effects of haloperidol.
- The findings suggest that neurotransmitter-neurohormone regulation of GH secretion in schizophrenia may not be significantly altered by standard haloperidol therapy.
- Further research is warranted to elucidate the complex mechanisms governing GH secretion in schizophrenia and its potential therapeutic implications.